| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:Nirsevimab
CAS:1989556-22-0
Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Nirsevimab (anti-RSV)
CAS:1989556-22-0
Package:100μg;1mg Remarks:K30791
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Nirsevimab
CAS:1989556-22-0
Purity:95% Package:100ug;500ug;1mg
|
Nirsevimab manufacturers
- Nirsevimab
-
- $2120.00
-
2026-05-21
- CAS:1989556-22-0
- Purity: 98.10%
- Supply Ability: 10g
|
| | Nirsevimab Basic information |
| Product Name: | Nirsevimab | | Synonyms: | Nirsevimab;Research Grade Nirsevimab (DVV02802);MEDI8897;Research Grade Nirsevimab;Nirsevimab (anti-RSV) | | CAS: | 1989556-22-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Nirsevimab Structure]() |
| | Nirsevimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Nirsevimab Usage And Synthesis |
| Uses | Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections[1][2]. | | in vivo | Nirsevimab (10-10000 μg/kg; i.m.) inhibits the antibody response in the respiratory mucosa of mice when pre-administered prior to RSV virus infection[2]. | Animal Model: | 3-week-old female BALB/c mice[2]. | | Dosage: | 10 μg/kg, 100 μg/kg, 1 mg/kg, 10 mg/kg | | Administration: | Intramuscular injection (i.m.); administer medication 24 hours prior to RSV virus exposure | | Result: | Inhibited the secretion of sIgA, mucosal IgA, and mucosal IgG in the offspring subsequent to the initial RSV infection. |
| | References | [1] Brady T, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023 Oct 11;14:1283120. DOI:10.3389/fimmu.2023.1283120
[2] Ma J, et. Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure. Front Immunol. 2024 Apr 30;15:1377374. DOI:10.3389/fimmu.2024.1377374 |
| | Nirsevimab Preparation Products And Raw materials |
|